Afamelanotide (SCENESSE®) is a synthetic α-melanocyte stimulating hormone analogue and first-in-class melanocortin-1 receptor agonist that is approved in the EU for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). It is administered subcutaneously as a biodegradable, controlled-release implant containing 16 mg of afamelanotide. This article reviews the clinical efficacy and tolerability of afamelanotide in EPP and summarizes its pharmacological properties. In the phase III trial, CUV039, afamelanotide treatment improved light tolerance in patients with EPP. Compared with placebo, afamelanotide treatment enabled patients to spend more time in direct sunlight without pain and increased the time to the appearance of the first symptoms of phototoxicity provoked by a standardized light source. Afamelanotide was generally well tolerated in this trial, with no drug-related serious adverse events reported. Commonly occurring adverse reactions included headache and implant-site reactions. Efficacy and safety data from earlier phase III trials are consistent with those from the CUV039 trial. Afamelanotide, approved in the EU for the prevention of EPP phototoxicity, represents a useful addition to the management of the disorder.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Lecha M, Puy H, Deybach J-C. Erythropoietic protoporphyria. Orphanet J Rare Dis. 2009;4:19.
Balwani M, Bloomer J, Desnick R, et al. Erythropoietic protoporphyria, autosomal recessive. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews®. Seattle: University of Washington; 2014.
European Medicines Agency. Scenesse: EU public assessment report. 2014. http://www.ema.europa.eu. Accessed 16 Feb 2016.
Sarkany RPE. The cutaneous porphyrias. In: Katsambas AD, Lotti TM, Dessinioti C, et al., editors. European handbook of dermatological treatments. Berlin: Springer; 2015. p. 763–80.
British Association of Dermatologists. Erythropoietic protoporphyria and X-linked dominant protoporphyria. 2014. http://www.bad.org.uk. Accessed 16 Feb 2016.
Poh-Fitzpatrick MB. Protoporphyria: background. 2014. http://emedicine.medscape.com. Accessed 16 Feb 2016.
Balwani M, Bloomer J, Desnick R. X-linked protoporphyria. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews®. Seattle: University of Washington; 2013.
Bonkovsky HL, Guo JT, Hou W, et al. Porphyrin and heme metabolism and the porphyrias. Compr Physiol. 2013;3(1):365–401.
Wahlin S, Floderus Y, Stål P, et al. Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics. J Intern Med. 2011;269(3):278–88.
Holme SA, Anstey AV, Finlay AY, et al. Erythropoietic protoporphyria in the UK: clinical features and effect on quality of life. Br J Dermatol. 2006;155(3):574–81.
Minder EI, Schneider-Yin X. Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert Rev Clin Pharmacol. 2015;8(1):43–53.
European Medicines Agency. Scenesse (afamelanotide) implant: EU summary of product characteristics. 2015. http://www.ema.europa.eu. Accessed 16 Feb 2016.
Haskell-Luevano C, Miwa H, Dickinson C, et al. Binding and cAMP studies of melanotropin peptides with the cloned human peripheral melanocortin receptor, hMC1R. Biochem Biophys Res Commun. 1994;204(3):1137–42.
Abdel-Malek ZA, Knittel J, Kadekaro AL, et al. The melanocortin 1 receptor and the UV response of human melanocytes: a shift in paradigm. Photochem Photobiol. 2008;84(2):501–8.
Barnetson RS, Ooi TK, Zhuang L, et al. [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol. 2006;126(8):1869–78.
Dorr RT, Dvorakova K, Brooks C, et al. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Photochem Photobiol. 2000;72(4):526–32.
Harms JH, Lautenschlager S, Minder CE, et al. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. Photochem Photobiol. 2009;85(6):1434–9.
Biolcati G, Deybach J-C, Hanneken S, et al. A randomized phase III trial of afamelanotide (Scenesse®), an agonistic α-melanocyte stimulating hormone analogue in the treatment of protoporphyria-induced phototoxicity [abstract no. O27]. Br J Dermatol. 2011;164(5):1143.
Clinuvel. Clinuvel reports positive results in phase III porphyria (EPP) clinical trial [media release]. 2010. http://www.clinuvel.com.
Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373(1):48–59.
Kochs C, Muehlenstaedt E, Siegesmund M, et al. The clinical spectrum of cutaneous effects of the synthetic α-melanocyte stimulating hormone analogue afamelanotide [abstract no. P49]. Br J Dermatol. 2011;164(5):1169.
Clinuvel. Clinuvel demonstrates positive treatment effect of afamelanotide in US phase II study [media release]. 2011. http://www.clinuvel.com.
Clinuvel. Completed EPP trials. 2014. http://www.clinuvel.com/en/scenesse/completed-epp-trials. Accessed 16 Feb 2016.
Biolcati G, Marchesini E, Sorge F, et al. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015;172(6):1601–12.
Lengweiler S, Kreim S, Barman-Aksözen J, et al. Evaluation of the immunogenicity of the synthetic α-melanocyte-stimulating hormone (α-MSH) analogue afamelanotide ([Nle4-D-Phe7]-α-MSH, Scenesse®) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-α-MSH antibodies. Skin Pharmacol Physiol. 2015;28(2):103–13.
US FDA. Orphan drug designations and approvals: afamelanotide. 2008. http://www.fda.gov. Accessed 16 Feb 2016.
During the peer review process, the manufacturer of afamelanotide was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
The preparation of this review was not supported by any external funding.
Conflicts of interest
Esther S. Kim and Karly P. Garnock-Jones are salaried employees of Adis/Springer, are responsible for the article content and declare no relevant conflicts of interest.
The manuscript was reviewed by: K. E. Anderson, The Departments of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, TX, USA; H. L. Bonkovsky, Department of Internal Medicine, School of Medicine, Wake Forest University, Winston-Salem, NC, USA; J. G. Langendonk, Department of Internal Medicine, Center for Lysosomal and Metabolic Diseases, Netherlands Porphyria Center, Erasmus MC, Rotterdam, Netherlands; H. W. Lim, Department of Dermatology, Henry Ford Hospital, Detroit, MI, USA; L. E. Rhodes, The Centre for Dermatology, University of Manchester, Salford Royal Hospital, Manchester, UK.
About this article
Cite this article
Kim, E.S., Garnock-Jones, K.P. Afamelanotide: A Review in Erythropoietic Protoporphyria. Am J Clin Dermatol 17, 179–185 (2016). https://doi.org/10.1007/s40257-016-0184-6
- Direct Sunlight
- Dermatology Life Quality Index
- Likert Score
- Lower Pain Intensity